Are In Vitro Metabolism and Drug Interaction Studies Critical for an Investigational New Drug Application?

Explore the critical role of in vitro ADME and drug-drug interaction (DDI) studies in the early stages of drug development through this informative webinar. Learn how understanding ADME properties and DDI risks can streamline decision-making, potentially avoiding unnecessary clinical studies, costs, and delays. Presented by Dr. Andrew G. Taylor, a research scientist at BioIVT with expertise in nonclinical drug interaction studies and GLP compliance, this hour-long session delves into the importance of these investigations for Investigational New Drug Applications. Gain valuable insights into how early ADME and DDI assessments can shape the drug development process and impact downstream activities.